RxDoctor Payments Data

Sultan Ripon, MD

Family Medicine · Auburn, NYNPI 1033648662

Payments from drug & device makers

$302in general payments, 2019–2025

Across 15 payments — averaging $20.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$81
  • Boehringer Ingelheim$77
  • Pfizer$50
  • Averitas Pharma Inc.$23
  • Medtronic$16
  • GSK$16
  • plus $39 from 3 others

What the payments were for

  • Food & beverage$302100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$302 in reported general payments places this provider in the 45th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$70,425
Medicare patients
192
Services billed
1,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide119$141,271
EliquisApixaban109$81,831
OzempicSemaglutide78$70,170
JardianceEmpagliflozin73$59,038
FarxigaDapagliflozin Propanediol46$52,874
Trelegy ElliptaFluticasone/Umeclidin/Vilanter84$52,249
JanuviaSitagliptin Phosphate55$45,288
RybelsusSemaglutide15$32,831
XareltoRivaroxaban17$22,300
Breo ElliptaFluticasone/Vilanterol32$17,673
Varenicline Tartrate71$14,985
MounjaroTirzepatide13$13,209
Janumet XrSitagliptin Phos/Metformin Hcl13$11,107
Repatha SyringeEvolocumab12$10,508
SymbicortBudesonide/Formoterol Fumarate25$7,867

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$15$154,480132 claims
Novo NordiskOzempic, Rybelsus$81$103,00193 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Shingrix$16$84,755162 claims
PfizerEliquis$50$81,831109 claims
Boehringer IngelheimJardiance$77$59,03873 claims
MerckJanuvia, Janumet Xr$14$56,39468 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 4,321 family medicine providers in New York.

Other family medicine in Auburn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →